Nadyphar Pharmaceutical JSC (UPCoM: NDP) recently held its 2026 Annual General Meeting of Shareholders, outlining a strategic revenue goal of 163 billion VND and officially introducing a new leadership board for the 2026-2030 term.
2026 Strategic Roadmap: Distribution and Growth
Following a robust 2025, where revenue reached 125 billion VND (a 16% increase) and profits exceeded expectations by 24%, Nadyphar is entering a pivotal transition phase.
-
Financial Targets: The company aims for 163 billion VND in revenue and 29 billion VND in pre-tax profit for 2026.
-
Market Pivot: To navigate the saturated generic drug market, Nadyphar is shifting focus toward the ETC (hospital/prescription) channel. For the OTC (retail) segment, the firm will prioritize partnerships with modern pharmacy chains rather than broad, scattered expansion.
-
Infrastructure: The company is currently optimizing its production rhythm after a period of factory upgrades and re-certification to meet increasingly stringent regulatory standards.
Leadership Restructuring for the New Term (2026-2030)
The 2026 AGM marked a significant shift in the company’s governance with the election of the 6th-term Board of Directors:
-
New Chairperson: Mr. Nguyen Van Thanh, a corporate finance expert, has been appointed Chairman of the Board, succeeding Mr. Ngo Nam Thang.
-
Vice-Chairperson: Ms. Dinh Thi Khoi, a seasoned professional with over 30 years in the pharmaceutical industry, takes on the role of Vice-Chairwoman.
-
Board Members: The board is rounded out by Mr. Nguyen An Giang, Mr. Tran Tan Dat, and Mr. Huynh Nguyen Thanh (who continues as General Director).
This blend of pharmaceutical expertise and financial leadership signals Nadyphar’s commitment to professionalizing its corporate structure and driving sustainable growth in the post-restructuring era.